Rumor Mill: Is BMS going on the sales block?

With Peter Dolan out the door [1] at Bristol-Myers Squibb, the choice for his interim successor is already sparking rumors that the company could be up for sale. James M. Cornelius helped orchestrate the Guidant buyout in his last post, which would make him the ideal person to negotiate a sale of BMS, analysts say. If nothing else, rumors of a takeover could be enough to put the company into play. Of course, this is all pure speculation, which Wall Street loves. But on Wall Street, today's hot rumor is often tomorrow's headline.

- read the article [2] on BMS from The Wall Street Journal (sub. req.)